Quick Answer
Edwards Lifesciences Corp reported Operating Income Loss of $1.26 billion for the year ending 2025.
- Edwards Lifesciences Corp showed a decrease of -8.3% in Operating Income Loss from 2024 to 2025.
- This data is from Edwards Lifesciences Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $298.30 million | Q2 2017: $241.00 million | Q3 2017: $214.00 million | Q1 2018: $252.50 million | Q2 2018: $252.10 million | Q3 2018: $248.90 million | Q1 2019: $274.20 million | Q2 2019: $267.50 million | Q3 2019: $294.30 million | Q1 2020: $358.10 million | Q2 2020: -$169.70 million | Q3 2020: $357.80 million | Q1 2021: $383.50 million | Q2 2021: $542.10 million | Q3 2021: $390.30 million | Q1 2022: $438.80 million | Q2 2022: $459.50 million | Q3 2022: $402.40 million | Q1 2023: $388.40 million | Q2 2023: $263.50 million | Q3 2023: $365.90 million | Q1 2024: $349.00 million | Q2 2024: $366.50 million | Q3 2024: $350.60 million | Q1 2025: $394.80 million | Q2 2025: $411.20 million | Q3 2025: $307.10 million.
- Over the full 10 years of available data (2016 to 2025), Edwards Lifesciences Corp's Operating Income Loss has grown by 68.3%.
- Historical annual values: Fiscal year 2025: $1.26 billion | Fiscal year 2024: $1.38 billion | Fiscal year 2023: $1.31 billion | Fiscal year 2022: $1.50 billion | Fiscal year 2021: $1.69 billion | Fiscal year 2020: $897.60 million | Fiscal year 2019: $1.15 billion | Fiscal year 2018: $748.20 million | Fiscal year 2017: $1.09 billion | Fiscal year 2016: $751.20 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: